NOVEN
TO HOLD ANNUAL SHAREHOLDERS’ MEETING ON MAY 14 |
BackPublic Invited to Listen to Webcast of Meeting
Miami, FL, May 12,
2003 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN), a leading developer
of advanced transdermal drug delivery technologies and prescription
transdermal products, will hold its Annual Meeting of Shareholders’ on
May 14, 2003, at 10:00 a.m. at Noven corporate headquarters, 11960
SW 144th Street, Miami, Florida. Live audio of the meeting will be
available at www.noven.com, and a rebroadcast will be available at
the same site. Please visit the site at least 15 minutes in advance
to download any required software.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is
a leading developer of advanced transdermal drug delivery technologies
and prescription transdermal products. Together with Novartis Pharmaceuticals
Corporation, Noven owns a profitable women’s health products
company called Novogyne Pharmaceuticals. Noven’s existing
products include advanced estrogen transdermal delivery systems
(including Vivelle-Dot®, licensed to Novogyne, and Estradot®,
licensed to Novartis Pharma AG) and combination estrogen/progestin
transdermal delivery systems (including CombiPatch®, licensed
to Novogyne, and Estalis®, licensed to Novartis Pharma AG).
With a range of additional products in development, Noven is committed
to becoming the world’s premier transdermal drug delivery
company. For additional information, visit Noven’s website
at www.noven.com.
Contact:
Investor & Media Contact
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
(305) 253-1916
Copyright © 2003 Noven Pharmaceuticals, Inc. All rights reserved.